Member Info for Timster

Worth bring this back to the top as we are talking about stuff that actually matters today.

He's never been wrong...

You got me tesa, I'm a b@stard.
You're right spend way to much time posting on here, making **** up to suit my narrative.

Unfortunately having held lots of different shares over the years I've done what wynbore warned us we should never do. On no research (well there was a woof woof systemzero post that swung it) I've fallen in love with Alan and gone all in (with what I can afford).
So yeah, proper twat...

They present a poster.

It is great news as you say. Should have been RNS'd really as the wider market don't know this detail from the preclinical data!

Awesome preclinical results though and totally consistent with ava6k, anyone would think the pre|CISION platform works!

Poster in section 20

https://www.aacr.org/meeting/aacr-annual-meeting-2023/schedule-at-a-glance/

Says posters at that time, plus
1:30 p.m.-5:00 p.m. Poster Session

1:00 p.m.-2:30 p.m. Major Symposia and Advances Sessions

1:00 p.m.-2:45 p.m. Clinical Trials Plenary

1:00 p.m.-2:30 p.m. New Drugs on the Horizon Session 1

So you are saying they are presenting at one of those sessions?

Oh well, I stand corrected, link?

Should really be an RNS

It's a poster though, not a presentation.

When you see the pictures of how many posters there are presented in a massive conference hall then it's not quite as exciting as you'd imagine.

That's my deramp for today, 20p coming...

Ava6k minimal side effects and NO cardiotoxicity seen at double the standard dox dose, pretty amazing stuff really.

Never mind that, I want to hear about valuation calculations...

I thought about it in 2019 and my dad's Bruce Lee.

Well they either have or they haven't.
It's either going to be 20 quid or 2 quid.

There are size buyers or not.

Ava3996 is either being presented at AACR or it isn't. (No RNS so can't be).

Dox doesn't behave like dox when it's cleaved from ava6k or it does.

Think that covers all bases.

"We are now in a position to proceed beyond the fourth cohort in the dose escalation study to even higher doses than originally anticipated, which is an unexpected and very positive development. The data being generated in the ALS-6000-101 study are providing detailed insights into the pre|CISIONTM platform which add significant value to the technology and confirm the potential of the pre|CISIONTM platform."

I don't think it's an assumption.

Safety Data Monitoring Committee (SDMC) has recommended continuation to higher dose cohorts with the aim of identifying a maximum tolerated dose (MTD) necessary to inform the dosing levels for the phase 1b and future studies. The Company expects that it will complete these additional cohorts during the first half of 2023.

Amateur's

Must be great being better than everyone else.

Trial? Don't worry yourself about that, it's not important.
I've been working on a valuation though which I plan to spam the board with shortly.

I can help I think:

Size unit buyer will / see 40 to 45 pre NY

Once NY bagels consumed expect sellers step aside '- 100 print 30 into close

Watch out for after hours prints size blue/red, doesn't matter.

"The data supports wider utility of the pre|CISION™ platform to target therapeutics to the tumor while reducing systemic dose-limiting toxicities."

It's what people forget in the valuations, it's a platform, capable of delivering numerous drugs.

Size buyers up early, large units